Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGT | O15294 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 8/20 | 0.36 |
| ▸ | HTR1A | P08908 | 7/20 | 0.36 |
| ▸ | PTDSS1 | P48651 | 7/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21099998 | 0.83 | OGT (0.46) | OGTF2CFDDRD2HTR1A | |
| SCHEMBL23790624 | 0.79 | GABRA1 (0.43) | OGTF2CFDDRD2HTR1A | |
| SCHEMBL16172349 | 0.78 | F2 (0.46) | OGTF2CFDDRD2HTR1A | |
| SCHEMBL5542039 | 0.78 | OGT (0.44) | OGTF2CFDDRD2HTR1A | |
| SCHEMBL5546637 | 0.75 | OGT (0.42) | OGTF2CFDDRD2HTR1A | |
| SCHEMBL16172328 | 0.75 | OGT (0.44) | OGTF2CFDDRD2HTR1A | |
| SCHEMBL434293 | 0.73 | OGT (0.50) | OGTF2CFDDRD2HTR1A | |
| SCHEMBL5541370 | 0.73 | OGT (0.40) | OGTF2CFDDRD2HTR1A | |
| SCHEMBL29749641 | 0.73 | KDM4E (0.53) | OGTCFDDRD2HTR1A | |
| SCHEMBL5542538 | 0.72 | OGT (0.39) | OGTF2CFDDRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210253580-A1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210163417-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2019-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | OGT 3681/4885F2 4345/4885CFD 4522/4885 |
| US-20210253580-A1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | HIPK1, HPGDS, IP6K1 | OGT 4178/4885F2 3685/4885CFD 4714/4885 |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | HIPK1, HIPK2, IP6K1 | OGT 3861/4885F2 4238/4885CFD 4830/4885 |
| US-20210163417-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HIPK1, HIPK2, IP6K1 | OGT 3861/4885F2 4238/4885CFD 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.